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Abstract
Transcranial Electrical Stimulation (tES) encompasses all methods of non-invasive
current application to the brain used in research and clinical practice. We present the first
comprehensive and technical review, explaining the evolution of tES in both terminology and
dosage over the past 100 years of research to present day. Current transcranial Pulsed Current
Stimulation (tPCS) approaches such as Cranial Electrotherapy Stimulation (CES) descended
from Electrosleep (ES) through Cranial Electro-stimulation Therapy (CET), Transcerebral
Electrotherapy (TCET), and NeuroElectric Therapy (NET) while others like
Transcutaneous Cranial Electrical Stimulation (TCES) descended from Electroanesthesia
(EA) through Limoge, and Interferential Stimulation. Prior to a contemporary resurgence in
interest, variations of transcranial Direct Current Stimulation were explored intermittently,
including Polarizing current, Galvanic Vestibular Stimulation (GVS), and Transcranial
Micropolarization. The development of these approaches alongside Electroconvulsive
Therapy (ECT) and pharmacological developments are considered. Both the roots and unique
features of contemporary approaches such as transcranial Alternating Current Stimulation
(tACS) and transcranial Random Noise Stimulation (tRNS) are discussed. Trends and
incremental developments in electrode montage and waveform spanning decades are presented
leading to the present day. Commercial devices, seminal conferences, and regulatory decisions
are noted. This is concluded with six rules on how increasing medical and technological
sophistication may now be leveraged for broader success and adoption of tES.
Despite this history, questions regarding the efficacy of ES remain including optimal
dose (electrode placement and waveform). An investigation into brain electric field and current
density produced by various montages that are historically relevant to ES was done to evaluate
how these montages effect the brain. MRI-derived head models that were segmented using an
automated segmentation algorithm and manual corrections were solved for four different
electrode montages. The montages that were used are as follows: Sponge electrode on left and
right eyes (active), Sponge electrodes over left and right mastoids (return); Sponge electrodes
above left and right eyes (active), Sponge electrodes over left and right mastoids (return); HighDefinition (HD) electrodes on AF3 and AF4 (active), 5x7 cm sponge on neck (return); HD
electrodes on AF3 and AF4 (active), 5x7 sponge electrode on Iz (return). A high concentration of
electric field was found on the optic nerve, with levels lowered as the electrodes moved further
away from the eyes. There was also a moderate current density on the amygdala, a center
involved with anxiety, as well as high electric fields on the brain stem which are centers for
sleep.
Using the models that were run for the electrosleep inspired montages the montage that
was selected for the proposed experiment was to use anodes on AF3 and AF4 with the cathode
on Iz. The anodes will be HD electrodes while the cathode will be a 5x7 cm sponge. Subjects
will be split into 4 groups of 8 people each and will receive two legs of stimulation spaced one
week apart. One leg will have current of 2 mA, 1 mA, 0.5 mA or sham while the other leg is all
sham and the order in which they receive it will be randomized. Subjects will be stimulated for
20 minutes at 100 Hz and will spend a total of 40 minutes during the experiment where they will
have their eyes recorded with an IR sensitive camera and they will be required to perform an
odd-tone response task. Subjects are expected to fall asleep faster with higher levels of current
and there is no added effect from baseline expected for subjects who receive sham stimulation.
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1. Introduction to transcranial Electrical Stimulation (tES)
1.1 Scope and Approach
Transcranial Electrical Stimulation (tES) encompasses all forms of research and clinical
application of electrical currents to the brain non-invasively using (at least one) electrodes on the
head. The dose of tES is defined by the electrode montage and the stimulation waveform applied
to the electrode (Peterchev et. al., 2012). There has been a resurgence of interest since 2000, but
“modern” tES developed incrementally over a century. This review provides the first
comprehensive organization of approaches and dose used in modern tES since 1900. Though
‘dose’ is used historically in different context, throughout this review we follow the strict
convention of Peterchev2012 (Peterchev et. al., 2012), where tES dosage is defined by electrode
parameters (including number, position, shape, composition) and all details of stimulation
waveform (including intensity and general waveform, and when relevant pulse shape, amplitude,
width, polarity, and repetition frequency; duration of and interval between bursts or trains of
pulses, and interval between stimulation sessions and total number of sessions, etc.).
This process involves defining the litany of terminology that has developed and evolved
around tES. We explain the terminology as used contemporarily by researchers. Particular
attention is paid to historically linked categories of tES, “streams”, of which we identify four that
span decades plus “contemporary” approaches (Figure 1): 1) Cranial Electrical Stimulation
(CES) descended from Electrosleep (ES) through Cranial Electro-stimulation Therapy
(CET), Transcerebral Electrotherapy (TCET), and NeuroElectric Therapy (NET); 2)
Electroanestheisia went through several periods of waning interest and resurgence when new
waveform variations were proposed including Transcutaneous Cranial Electrical Stimulation
(TCES), Limoge, and Interferential Stimulation; 3) Polarizing or Direct Current Stimulation
includes recent transcranial Direct Current Stimulation, Transcranial Micropolarization,
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High-Definition transcranial Direct Current Stimulation (HD-tDCS) and Galvanic
Vestibular Stimulation (GVS); 4) Electroconvulsive Therapy (ECT), initially called
Electroshock Therapy, evolved in technique and dose, such as Focal Electrically
Administered Seizure Therapy (FEAST); 5) Finally, we categorize “contemporary”
approaches that have been explored intensely over the last decade, such as transcranial
Alternating Current Stimulation (tACS), transcranial Sinusoidal Direct Current
Stimulation (tSDCS), and transcranial Random Noise Stimulation (tRNS). Though
analogues to these contemporary approaches can be identified in earlier literature, contemporary
methods contain dose features that motivate us to consider them novel as a category.
Contemporary approaches to some extent reflect a “re-boot” of tES approach, typically
employing basic, well documented, and well-defined waveforms (e.g. one sinusoid; Paulus,
2011) in contrast to the increasingly complex waveforms developed (though not always justified)
over decades in some streams.
As our technical focus is on dose clarification and classification, we minimize comments
on the clinical efficacy or safety of any approaches except in special cases where findings
resulted in historically notable and sudden changes in dose or terminology. We note specific
conferences and regulatory agencies that helped identify and shape the field of transcranial
Electrical Stimulation including establishing terminology. Commercial (brand) names of devices
are noted ad hoc for context and linked to dose terms where appropriate. We do not comment
directly on mechanisms but emphasize that dose determines electric field in the brain (Peterchev
et. al., 2012) which, in turn, gives rise to neurophysiological responses (Bikson et. al., 2004) and
sustained brain function changes (which may depend on N-methyl-D-aspartate receptor; Li and
Tsien, 2009); thus understanding the dose is a prerequisite to understanding mechanisms.
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We do not address magnetic stimulation approaches or electrical stimulation approaches
not targeting the brain, or non-electrical therapies, except in specific cases to indicate the
terminology used in these other approaches for the purpose of overall clarity of nomenclature.
We did not attempt to perform an exhaustive cataloging of tES publications.
Though we do not comment on efficacy, the nominal indications for tES use (intended
clinical outcomes) are noted when contextually relevant, especially for many historical streams
(defined above). There are instances in which researchers used terminology to describe a dose in
a manner potentially inconsistent with typical historical norms of dose associated with that
terminology - when these papers provide sufficient dose details these deviations are noted. Our
summary aims to reflect the most typical doses used across the majority of studies (Table 1). In
addition, to promote a more comprehensive and systematic dose classification, we propose new
categories for those waveforms using pulsed stimulation in table 2 (transcranial Pulsed Current
Stimulation, tPCS).
It is important to emphasize that the specifics of tES dose (electrode montage, waveform,
intensity and duration) determine brain modulation –evidently the given therapy name is
incidental and often reflects a historical bias and varying intended use. In this sense, a strict
approach would involve ignoring all historical nomenclature and consideration of specific dose.
However, this ideal approach is problematic due to the following reasons: First, in most cases the
complete dose details are not provided (e.g. electrode size, waveform details); Secondly,
investigators often adjusted (tweaked) dose on a case-by-case basis, thus resulting in hundreds of
potential categories.
Though decisions by regulatory agencies, notably the Food and Drug Administration
which regulates the marketing of medical devices in the US, plays heavily in the commercial
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viability of various tES technologies we note 1) FDA approval is a negotiation around a specific
product and settings initiated between company and the FDA; 2) As such a majority of devices
and waveforms have simply not been reviewed by the FDA, and a lack of FDA approval is not a
verdict on safety or efficacy; 2) FDA approval for an indication and inclusion criterion is by
definition limited to this “label”; 3) FDA “cleared” devices have ‘grand-fathered’ regulatory
clearance with no verdict on efficacy or safety and moreover devices with a “510k” FDA
clearance based on these devices often provide varied doses. In Europe, a CE-mark can typically
be obtained by compliance with electrical and mechanical production standards with no further
endorsement of safety or efficacy in medical use. Much of the historical development of tES
predates any regulatory environment and a majority of ongoing research is not designed to
satisfy the FDA. The regulatory status of tES remains in infancy.
Ultimately, this review should serve as a road map for further investigation of classical
techniques and appreciation of the origin of recent techniques. Even experienced researchers
may remain unclear about basic features in classical literature, for instance, did Electrosleep or
CES use DC? At the same time, the broad view taken in this review should be a useful
introduction to new investigators and clinicians. More generally, we are interested in the
narrative of tES development with respect to current tES clinical studies. Research into tES
mechanisms in clinical outcomes has been active for over a century. Some specific dose
approaches (with indications) generated increased interest only later to be largely abandoned –
the context for such waxing and waning of enthusiasm for specific historical approaches, may be
relevant for current clinical efforts. Similarly, the history of tES development reflects parallel
developments in pharmacology including narcotics – which again may provide perspective on
current clinical trials (Brunoni et. al., 2012).
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Our intention is that this historical dose analysis of tES, with requisite clarification and
definition of dose terminology, will provide context on current approaches and facilitate rational
investigation and adoption. To this end, we conclude this review with a proposal on five recent
clinical and technical developments that may be leveraged toward broader adoption of tES in
medicine namely: 1) Recognition of limitations in drugs that tES may overcome; 2)
Advancement in the understanding of mechanisms and biomarkers of responsiveness; 3)
Integration with cognitive and physical therapy supporting “functional targeting”; 4) Advanced
montages supported by computational models; 5) General advancements in electronics and
communication integrated into tES.
Unless otherwise specified we follow the following naming convention: Direct Current
(DC) is used here to refer to uninterrupted unidirectional current flow. Either monophasic
(unidirectional ramp up and down) or biphasic (bidirectional) pulses are referred to as pulsed
current (PC). Alternating Current (AC) is used here to refer to sinusoidal waveforms.

1.2 Historical Development
Our historical review initiates circa 1900 – though evidently the history of electrical
stimulation is longer, several “streams” of tES we identified initiate around this period,
(Robinovitch, 1914), including Electrosleep (ES) and Electroanesthesia (EA). These two
approaches may in fact have been developed together with distinct terminology referring to the
intended indication for use. Some of the earliest (if incomplete) documentation of tES devices
also dates from this period, which in turn allows us to better specify dose. Notably, in 1914,
Louise Robinovitch summarizes:
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Figure 1: A general timeline of ES/EA noting key points in the history from 1902 until 2011 as well as their
relation to DC stimulation. A brief history of DC stimulation is also presented in this table. Other cranial
therapies are mentioned for a complete cranial stimulation history and non-cranial therapies are mentioned for
their connection to ES/EA. Arrows are used to connect historically related points while the horizontal purple
lines are used to point out DC use in historically pulsed applications.
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“Nothing but storage batteries of large capacity, 100 to 200 amperes, should be used.
The current used for the patient and the motor should come from two separate sources. The
current to be used for the patient is connected with the inlet binding posts of a graphite rheostat.
A wire potentiometer should not be used because it brings troublesome inductance into the
circuit… The current is interrupted on the negative pole ; this pole is connected as follows : a
wire connects the outlet binding post of the potentiometer(negative pole) with the wheel
interrupter, a milliampere meter, a switch, and finally a resistance box (Wheatstone bridge or any
graded resistance).The other binding post of the potentiometer (positive) is connected directly
with the bridge. The resistance put into the circuit is from 300 to 500 ohms. … The circuit is then
closed by means of the switch. A voltmeter is connected in shunt; all the other instruments are in
series. The wheel interrupter is put in such a position as to allow the passage of the direct current
without interrupting it (the wheel is not revolving). The voltmeter indicates, say, 40 volts; the
milliamperemeter indicates, say, 20 milliamperes. Now the wheel interrupter is made to revolve
by means of the motor, say, 1,500 to 2,000 times per minute. Whatever the amperage is while the
wheel is interrupting the direct current, it is the aim to regulate the period of the passage of the
current so as to have it pass only 1/10 of the time, 9/10 being lost. This is accomplished by
changing the position of the adjustable contact lever in relation to the fixed lever on the wheel,
while the latter is revolving. Keep on adjusting the movable lever until the milliampere meter
that registered 20 milliamperes when the wheel was stationary now registers only 2 milliamperes
while it is revolving. The period of the passage of the current is now 1/10... Now reduce the
current to zero with the potentiometer, break the circuit by opening the switch, take out the
bridge and substitute for it an animal or a patient. The wheel is made so that it can interrupt the
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current from 6,000 to 12,000 times per minute, according to the speed of its rotation.”
(Robinovitch, 1914).
From this description we may surmise this particular device was voltage controlled (~40
V) but that current was calibrated (e.g. 20 mA) under a temporary resistive load, with
monophasic stimulation at >100 Hz with 10% duty cycle (1 ms pulse width).

1.2.1 Developments from Electrosleep to Cranial Electrotherapy Stimulation
Electrosleep (ES), in short, is the name for tPCS methods by which the brain was
stimulated in order to induce a sleep-like state in the subject. The first studies on electrosleep
initiated in 1902 (Robinovitch, 1914; Gilula and Kirsch, 2005), however, the first clinical report
of electrosleep was published 12 years later by Robinovitch (Robinovitch, 1914; Brown, 1975).
Apparently, much of the research regarding electrosleep was conducted in Russia up until 1953,
when clinical use of electrosleep began in Europe (Smith, 2006). New approaches were
developed mostly in Europe, such as changing electrode position from covering the eyes to
locations around the eyes, presumably to “…reduce optic nerve irritation” (Brown, 1975;
Obrosow, 1959). Electrosleep dose waveform was typically pulsed at 30-100 Hz, but at least one
(unsuccessful) case of use of DC current was documented (Brown, 1975). After 1963, an
increased use of electrosleep in the United States was noted. Three years later, the first
symposium on Electrosleep and Electroanesthesia was held in Graz, Austria (Knutson, 1967;
Smith, 2006). At this symposium it was reasoned that electrosleep does not actually induce sleep,
rather it is an indirect side effect of the relaxing effects of stimulation. Therefore, the name of
electrosleep was changed to Cranial Electrostimulation Therapy (CET) (Knutson, 1967). This
was the first of several changes of the name of Electrosleep over the next few decades, often with
notable changes in dose. Some devices that were used during this time were: Jungbluth CET-1,
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Tritronics 100, Somatron 500, Lafayette 72000, Lafayette 72200, General Medical Industry 11007-1, Vreeland Oscillator, and the Leduc Stimulator (Brown, 1975; Figure 2). There was also
a recent study done in 2009 where a device called the Pulsatilla 1000 was utilized to treat pain in
patients (Gabis et. al., 2009).
In 1969, Transcerebral Electrotherapy (TCET) was proposed as another alternative
name, which was adopted by some authors (Brown, 1975). In 1977, electrosleep and its
derivatives went under review by the FDA and in 1978 were classified as a Class III device for
the treatment of Anxiety, Insomnia, and Depression (FDA Executive Summary, 2012) under a
nominally temporary “grandfather” clause. However, such devices were re-named as Cranial
Electrotherapy Stimulation (CES) (Kirsch, 2010). The FDA status of CES remains debated
and not fully addressed to the present day (FDA Executive Summary, 2012).
In 1972 a new method and device, which consists of the Neurotone 804 and 901(Figure
2) and these are not related to the Neurotone 101 mentioned later, of electrosleep called
NeuroElectric Therapy (NET) (Patterson, 1976; Patterson, 1979) was developed in England.
Though NET preceded many modern CES devices (see below) it may have influenced the doses
they used decades later. Another notable device, produced after the name change to CET, was
the Neurotone 101, which was based on a Russian ES device brought to the United States.
Although the Neurotone 101 is no longer in production, it was the first device to be approved by
the FDA as a CES device (Kirsch, 2010) and all subsequent CES devices, such as the Alphastim, the Oasis Pro and the Fisher-Wallace Stimulator (Figure 2), approved by the FDA were
through a 510k process claiming equivalency, either direct or descendent, to the Neurotone 101.
This ‘administrative’ equivalency is not reflected in identical dose of current CES devices, which
in fact are often marketed to provide a novel (“exclusive”) dose. Given the variation of CES

15
device outputs, we note these devices are not equivalent in regards to dose, and that
safety/efficacy evidence from one device cannot support performance of other CES devices or,
for that matter, a consensus on performance by a regulatory agency such as the FDA.
Modern Cranial Electrotherapy Stimulation (CES) is thus a historical descendant of
Electrosleep even as dose and indications have continuously evolved. The FDA sanctioned CES
in 1978 through a “grandfather clause” and since did not advance a regulatory consensus, even as
more variants were developed.

1.2.2 Developments from Electroanesthesia to Limoge Current and Other
Related Methods
Electroanesthesia (EA), in short, was intended to induce anesthesia in the subject using
high frequency stimulation so that chemicals did not have to be used pre-surgery.
Electroanesthesia studies started in 1903 but were first known as Electronarcosis (EN)
(Robinovitch, 1914; Brown, 1975; Limoge et. al., 1999). Russian scientists used the term
“electroanesthesia” to describe local anesthesia while “electronarcosis” described general
anesthesia (Brown, 1975). However, electroanesthesia stopped being referred to as local, applied
to the periphery, and began to be known as general anesthesia, now applied to the brain.
Therefore, in this review, EA will refer to general anesthesia. One of the earliest published
claims of success in regards to EA during surgery was made in 1914 by Leduc (Brown, 1975;
Smith, 1971).
Louise Robinovitch, a scientist that worked with Leduc, summarizes: “In 1890
d'Arsonval found that high frequency currents above 3,500 and not over 10,000 periods per
second caused a certain degree of anesthesia. In 1892, or earlier, Hutchinson found that induction
currents, frequently interrupted with the ribbon vibrator that he had invented, caused anesthesia.
In 1901 Mile Pompilian produced anesthesia in frogs by subjecting them to induction currents
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frequently interrupted by means of a revolving wheel with 12 insulated segments designed by
herself. In 1902 Leduc and Rouxeau experimented with direct currents interrupted by means of a
revolving wheel designed by them.” (Robinovitch, 1914).
Louise Robinovitch also worked with a stimulator that produced alternating currents
called the Vreeland Oscillator (Robinovitch, 1914). The Vreeland Oscillator worked using a tube
filled partly by mercury with three anodes, two resistors, two choke coils, two inductive coils and
a variable condenser (Aardal, 1920).This system, when started by one of the anodes, would cause
two arcs to appear and for the currents to be generated, the magnetic fields from the inductive
coils would cause the arcs to oscillate causing one arc to become bigger than the other in an
alternating fashion. The frequency of the device could be calibrated using a vibrating tuning fork
(Aardal, 1920).
Safety and tolerability concerns, and the development of early chemical anesthetics, may
have contributed to quelling interest in EA. In the 1940s research on EA focused on chemical
primers being used in conjunction with EA (Brown, 1975; Knutson et. al., 1956). Soon after,
research appeared to largely halt again presumably due to severe side effects. For example,
severe side effects such as cardiac arrest, respiratory arrest and apoplexy were observed
(Knutson, 1956; Smith et. al., 1967). A third wave of research in EA initiated after a study was
published in 1960, proposing a new EA approach to reduce side effects: “...a combination of
pulsed and direct currents…the very slow increase of current levels… and…the use of a
generator that minimized changes in electrode impedance resulting from polarization ”(Brown,
1975; Smith et. al., 1966).
Research into EA dosage continued and the term Transcutaneous Cranial Electrical
Stimulation (TCES) was adopted around 1960-1963, with the intended use to “potentiate some
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drug effects, especially opiates and neuroleptics, during anesthetic clinical procedures… [with
the goal of] drastic reduction in pharmacologic anesthetic agent and reducing post-operative
complications” (Limoge et. al., 1999). Even though the term TCES was not adopted until the
early 1960s, similar protocols were used as early as 1902 by Leduc (Limoge et. al., 1999). In
1951, Denier proposed that high frequency trains of 90 kHz could be used to avoid muscular
contraction (Limoge et. al., 1999). Three years later, Knutson (1954) claimed that alternating
currents at 700 Hz should be applied, but this was abandoned in 1958 due to cardiovascular
complications (Limoge et. al., 1999). In 1957, investigators in the Soviet Union attempted to add
a DC component to Leduc’s currents but, as claimed by an American scientist Robert Smith, it
resulted in a collection of undesirable side effects (Smith et. al., 1966). In1963, Aimé Limoge
modified the TCES dose and called it Limoge Current (Limoge et. al., 1999). In 1964, a study
claimed pulsating currents are more effective than direct currents for the induction of EA
(Brown, 1975). Another study suggested that the use of pure DC for EA required high intensity
of approximately 40 mA (Brown, 1975).
In 1965, Interferential Stimulation (IS) was proposed by Russian scientists (Brown,
1975). Interferential Stimulation consisted of having two pairs of electrodes energized with sine
waves of slightly shifted frequencies. The intention of this approach was that through pulsation
the higher frequencies would create a lower frequency, where the two frequencies intersect. This
was clinically desired as low frequencies were presumed more efficacious in inducing EA
whereas higher frequencies were more desirable for tolerability (i.e. reduced skin pain, sensation,
etc.) (Brown, 1975; Smith, 1971). We note, however, that under the assumption that the timeconstant in neuronal membranes effectively filters out all high frequency signals (> 100 Hz;
Bikson, et. al., 2004) then regardless of how they are combined and modulated, these signals
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would be neurophysiologically inactive (even though power is modulation). Aspects of
combining low and high frequencies, perhaps analogous to Interferential Stimulation but though
with a single electrode appear, are suggested by manufacturers as relevant for some later CES
technologies.
In the development of EA, Fading has two different meanings, decrease in anesthetic
state (Smith et. al., 1968) or increase in tolerability. In the first case, fading indicated a decrease
in the subjects’ anesthetic state while the dosage was kept steady (Smith et. al., 1968).
Maintenance of anesthetic state was accomplished by either reduction of frequency or increase of
current (Smith et. al., 1968) consistent with modern neurophysiological analysis indicted
increasing intensity or decreasing frequency increases polarization (Bikson et. al., 2004). Fading,
more recently, has been used to increase tolerability by incremental increase to the maximum
dosage under the premise that sensation at the skin adapts to current flow. Indeed, fading is a
common method used in many contemporary tES approaches such as tDCS. TCES has been
studied to reduce post-operative analgesic requirements (Nekhendzy et. al., 2010), as are other
contemporary tES approaches (Borckardt et. al., 2011).
While modern tES is concerned with the treatment of a broad range of pain disorders
(Zaghi et. al., 2011; Brunoni et. al., 2012; Brunoni et. al., 2013) and have been tested on acute
(experimental) pain (Mylius et. al., 2012; Borckardt, et. al., 2012) and post-operative (Borckardt
et. al., 2013), the clinical goal of modern tES is typically chronic pain relief and thus effects that,
if less dramatic, outlast stimulation. Historical EA/TCES used current intensities that were
typically well above those used in contemporary tES. None-the-less, the reported profound
effects EA/TCES and approaches to enhance tolerability may be of relevance
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1.2.3 DC Stimulation
Direct current stimulation has been used intermittently as a component in both ES and
EA. In 1957, a DC bias was added to ES, which is traditionally applied using only AC or PC.
The advent of TCES, around 1960-1963, in the third resurgence of EA research, also
incorporated a DC bias. In 1969, pure direct current stimulation was investigated for inducing
anesthesia (Brown, 1975). However, it was not until 1964 that preliminary studies heralding
modern transcranial Direct Current Stimulation (tDCS) were published (Redfearn and
Lippold, 1964).
In 1964, Redfearn and Lippold investigated polarizing current for treatment of
neuropsychiatric diseases (Redfearn and Lippold, 1964), their use of prolonged (minutes) or
stimulation was motivated by animal studies showing that prolonged direct current stimulation
could produce lasting changes in excitability (Bindman et. al., 1964). While further open pilot
studies and clinical observations suggested efficacy (Baker, 1970; Nias and Shapiro, 1974;
Ramsay and Schlagenhauf, 1966), a following negative controlled trial (Arfai et. al., 1970) seems
to have halted investigation (at least as published in western journals) for several decades.
The neurophysiological basis of neuromodulation using short duration tDCS was
investigated by Priori and colleagues in 1998 (Priori et. al., 1998). Shortly after, Nitsche and
Paulus established that prolonged (minutes) tDCS could produce lasting and polarity specific
changes in cortical excitability (Nitsche and Paulus, 2000) followed by pilot clinical studies
(Bolognini et. al., 2009) for indications spanning depression (Datta et. al., 2008), pain (Datta et.
al., 2008), epilepsy (Datta et. al., 2008), and a broad range of neuropsychiatric disorders (Datta
et. al., 2008).TDCS is further explored for rehabilitation including after stroke (Datta et. al.,
2008). Moreover, due to the perceived safety of tDCS it was initially validated for
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neurophysiological changes in healthy subjects and continues to be investigated in healthy
individuals for changes in behavior and cognitive performance (Datta et. al., 2008).
In 2007, High Definition transcranial Direct Current Stimulation (HD-tDCS) was
proposed as a focalized form of tDCS (Datta et. al., 2008; Datta et. al., 2009). HD-tDCS
electrodes were designed for increased charge-passage capacity through smaller a contact area
(Minhas et. al., 2010), arranged in arrays that can be optimized per indication (Dmochowski et.
al., 2011). HD-tDCS montages tested include the 4x1 configuration (Edwards et. al., 2013) as
well as and individually optimized arrays (Dmochowski et. al., 2013). The focalization of current
with HD-tDCS is an improvement upon tDCS where previously a broad area would be
stimulated and now specific targets can be stimulated. Some of the devices that have been used
are the Schneider (tDCS), Soterix Medical 1x1 (tDCS) and the Soterix Medical 4x1 (HD-tDCS)
(Figure 2).
Transcranial Micropolarization is a technique investigated in Russia which is a
modified version of tDCS using small electrodes instead of pads as well as currents up to 1 mA
that are claimed to be “weak” (Shelyakin and Preobrazhenskaya, 2009). Galvanic Vestibular
Stimulation (GVS) is being investigated for effects on ocular and postural movement (Watson
and Colebatch, 1997). Alongside GVS, Caloric Vestibular Stimulation (CVS) is under
investigation due to similar areas being targeted by stimulation. However, CVS does not utilize
electricity, rather irrigation of the ear canal using cold or warm water (Miller and Ngo, 2007).

1.2.4 ECT
Initially developed circa1933, Electroconvulsive Therapy (ECT) (Gilula and Kirsch,
2005; Abrams, 2002), used repetitive high-intensity pulses to trigger seizures. A common
moniker used for ECT is Electroshock Therapy (EST). ECT was cleared by the FDA for
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Depression in 1976 as a “pre-amendment device” (“grandfathered” similar to the process CES).
In 2011 the FDA summarized: “The ECT procedure was first conducted in 1938 (Rudorfer et.al.,
1997). Two Italian physicians, Ugo Cerletti and Lucio Bini, guided by a theory holding an
antagonistic relationship between seizures and psychosis, became the first to use electricity to
induce a therapeutic seizure in humans (Faedda et. al., 2010).They reported on the first treatment
of a patient using this method in 1939 (Bini, 1995). Joining a number of other somatic-based
therapies of the era (prior to the advent of modern pharmacotherapy), ECT became a popular
intervention for psychiatric conditions. Since that time, the use of ECT has [fluctuated]. In the
1950’s and 60’s, with the development of drug therapies for psychiatric conditions, and due to
concern for serious device related adverse events, the use of ECT in the U.S. declined (Lisanby,
2007). However, in recent years, interest in and use of, ECT has experienced a resurgence; ECT
use in the U.S. has been estimated at 100,000 individuals receiving this treatment annually
(Hermann et. al., 1995). Reflecting the greater proportion of women who suffer from major
depression, two-thirds of patients who receive ECT are women (Olfson et. al., 1998). In clinical
practice, ECT is generally considered after failure of one or more antidepressant medication
trials, or when there is need for a rapid and definitive response (APA 2001; p. 23-24). ECT has
been used to treat a variety of psychiatric disorders. These disorders include: Depression
(unipolar and bipolar), Schizophrenia, Bipolar manic (and mixed) states, Catatonia, [and]
Schizoaffective disorder. The evidence supporting the effectiveness of ECT for each of these
indications is variable.” A controversial topic in ECT research is if clinical changes require the
induction of a seizure, or if seizures are not always mechanistically pivotal such that the
generation of high-intensity electrical fields can lead directly to changes (e.g. raising the
possibility take the “convulsive” out of ECT).

22
Whereas the development of drug therapies may have arrested the development of other
tES treatments, it is notable that even “after the advent of antidepressant medications and other
pharmacologic treatments, only electroconvulsive therapy (ECT) remained as a nonsurgical and
non-pharmacological tool originating in those early years still in routine use over seven decades
later” (Rosa and Lisanby, 2012), though the authors continue, “Today we are experiencing a reemergence of non-pharmacological somatic treatments, possible because of limitations of
medications for a significant percentage of patients…and because engineering advances have
enabled previously unprecedented tools for noninvasive neuromodulation” (see section 4).

1.2.5 Contemporary approaches
Two contemporary forms of tES are transcranial Alternating Current Stimulation
(tACS) and transcranial Random Noise Stimulation (tRNS) (Paulus, 2011). Both tACS and
tRNS use relativity low-intensity current and are being investigated for therapeutic effects
(Paulus, 2011). A modified protocol for tACS is transcranial Sinusoidal Direct Current
Stimulation (tSDCS) (Antal et. al., 2008) where the stimulation is monophasic due to a DC bias
added to the sinusoid.
Another form of tES that was used by Marshall and colleagues (Marshall et. al., 2006)
consisted of monophasic trapezoidal pulses with a DC bias, frequency of 0.75 Hz. The pulses
used by Lisa Marshall and colleagues were investigated for their effects on learning. The subject
would learn the task before sleeping, and be tested on the task the next morning. The stimulation
would occur 4 minutes after stage 2 sleep occurred for the first time, without reversion to stage 1,
and stimulation continued at 5 minute intervals with a 1 minute break throughout the night
(Marshall et. al., 2006).
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1.2.6 “TES”
The first mention of “TES” was 1980 in a study by Morton and Merton (Merton and
Morton, 1980). “TES” uses single (isolated) high-intensity pulses to typically activate motor
cortex and stimulate motor response. This early use of “TES” resulted in many contemporary
investigators associating “TES” with only supra-threshold, short-duration pulses delivered
randomly, with low frequency. In this review, we use tES in the broader sense and “TES”
(quotes and capitals) to specify the use of supra-threshold low frequency pulses. “TES”
technique can be painful and was not investigated for therapeutic applications, but remains used
for diagnostic purposes under anesthesia (Zentner et. al., 1989; Macdonald, 2002; Kalkman et.
al., 1992). For the purposes of experimental stimulation in awake subjects, with low-frequency
supra-threshold intensity, contemporary investigators often use Transcranial Magnetic
Stimulation (TMS) instead, as it is more tolerated for these purposes. “TES” continues to be used
for intra-operative evaluation in anesthetized subjects and “TES” was first “cleared” by the FDA
in 2002 for this purpose. TES thus stands apart from other tES approaches in that it is intended
use it for neurophysiological evaluation rather than treatment, and as such there is little debate
over its efficacy which is manifest in triggering evoked muscle responses.

1.2.7 Non-Cranial Therapies
Non-cranial electrical therapies are mentioned here only in context of historical relevance
to cranial therapies. Given the similarities in waveform and timing, the advent of Limoge
Currents apparently informed the developed of Transcutaneous Electrical Nerve Stimulation
(TENS) in 1974, which was however applied to the periphery for varied indications including
pain, neuromuscular, and orthopedic. The relevance of the vast literature on TENS (including
healing if damaged tissues) back to the central nervous system remains unaddressed and
compelling. Microcurrent Electrical Therapy (MET) was developed approximately in 1984
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and was incorporated into CES devices such as the Alpha-stim 100 (Limoge et. al., 1999; Kirsch,
2010). Joseph Ventura commented on hurdles to broad and consistent technology acceptance that
is prescient for current concerns with cranial therapies (also see size rules below): “At the same
time this was happening, the market was flooded with inexpensive imitation devices from
overseas. These devices did not use the Wing parameters [the same dose as original devices] and
did not work like the clinical units. But because they were labeled as Microcurrent, customers
thought they were using the real thing but didn’t get real results. Microcurrent began its long,
slow descent into irrelevancy.”
Another non-cranial therapy, ElectroAcupuncture, is indicated for local anesthesia in
combination with anesthetic primers and combines EA (in this case local EA) and acupuncture
(Christensen et. al., 1993). Iontophoresis is an FDA approved technology using sustained direct
current to facilitate transdermal transport of ions or drugs, typically limited to the periphery.
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Figure 2: The images shown in the figure above are devices that have been used since 1900 for
the purpose of transcranial stimulation. Each row represents a different period of stimulation
in regards to terminology. For the lack of a device image, a schematic of the Vreeland
Oscillator was used due to the fact that it is a pure AC stimulator that was used in early ES/EA
applications. All images have been approved for use by the companies or persons who hold the
copyright to the images.

1.3 Dosage
This section aims to further clarify the stimulation dose associated with select
approaches. It is noteworthy that even early in transcranial electrical stimulation development it
was recognized that: 1) Stimulation waveform along with electrode positions (stimulation dose,
Peterchev et. al., 2011) can be varied to change efficacy and safety; 2) the value of current
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controlled stimulation in contrast to voltage controlled stimulation; and 3) that electrode design
including the use of a fluid/gel (electrolyte) buffer between the metal electrode and skin
increases skin tolerability (Merrill et. al., 2005). None-the-less, ad hoc and often poorly
documented variations in dose are coming in the literature, a matter that remains of concern to
this date (Peterchev et. al., 2011). Unless otherwise stated, we presume that stimulation was
current controlled.
Though we divide dose by category below, certain over-arching developments can be
noted for both electrode design and waveform. “Active” and “return” terminology for electrodes
reflect only the brain target of interest with “active” located nearer the target; evidently both
electrodes will affect brain function and indeed the position of the return determines “active”
current flow (Bikson et. al., 2010). The early approach to tES involved two “active” electrodes
placed directly over the eyes with two “return” electrodes, presumably to facilitate active current
delivery through the optic foramina. Active electrode positions around the eye (e.g. supraorbital) were explored, as well as reducing the number of active electrodes (e.g. single electrode
on the forehead) or using just one return electrode. After 1970, approaches using electrodes on or
around the ears were explored (though much earlier examples of ear electrodes are noted), with
presumed current flow to deeper brain structures (Datta et. al., 2013). In the 1980’s, approaches
using tES showed that current could be delivered focally using small closely-spaced electrodes
on the scalp (for example as indicated by motor responses). After 2000, contemporary
approaches (e.g. tDCS, tACS) used reduced currents and large-sponge electrodes (Nitsche and
Paulus; 2000) with an “active” electrode placed over the nominal target. Though the use of larger
electrodes and distant electrodes precludes focal stimulation (Datta et. al., 2009) of cortex or
avoidance of deep brain structures (Dasilva et. al., 2012), functional effects of tDCS may be
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shaped (Nitsche et. al., 2007).

Recent generations of technologies using arrays of small High-

Definition (HD) electrodes are intended to allow focal brain stimulation and more precise control
of and how deeper structures are targeted (Datta et. al., 2008; Datta et. al., 2009; Dmochowski et.
al., 2011; Dmochowski et. al., 2013; Edwards et. al., 2013; Minhas et. al., 2010). Though
explored initially for delivering DC waveforms (HD-tDCS; Borckardt et. al., 2012; CaparelliDagquer et. al., 2012; Kuo et. al., 2013; Minhas et. al., 2010), stimulation with HD-tES arrays
may be leveraged to focalize delivery of any waveform (e.g. HD-tACS, HD-tRNS, HD-tPCS…).
In the context of waveform, a notable overarching progression was: 1) From basic
waveforms (often limited to existing stimulation hardware), to increasingly complex and
customized waveforms motivated by the perception that increased efficacy, safety, or tolerability
was needed; 2) Increasing complexity and (proprietary) uniqueness especially developed in
commercial devices (e.g. CES); 3) Leading to a reversion to the most basic waveform after 2000,
associated with

a resurgence of clinical

interest

using standardized and defined

approaches. Early intended uses focused on short-term effects motivated investigators to explore
increased intensities (e.g. sleep, anesthesia), while interest in chronic diseases (e.g. depression) is
consistent with efforts using reduced (well tolerated) current intensities and increasingly
prolonged (repeated session) use.
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Table 1: Dosages of the various cranial stimulation methods are shown. The year at which the form of stimulation
came about is written with the stimulation method. Each method is connected to an electrode placement as well as
a waveform used.
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1.3.1 Electrosleep and derivative techniques
The dosage for electrosleep has evolved since it first was investigated in 1902 (Gilula and
Kirsch, 2005). Dosage used for electrosleep consisted of electrode placement over each eye and a
return electrode over the mastoid, with a waveform consisting of 100 Hz monophasic
(Robinovitch, 1914) pulses between 2-25 mA (Robinovitch, 1914; Knutson, 1967). The pulse
width was between 0.3 to 0.6 ms and stimulation duration lasted from 20 to 60 minutes
(Robinovitch, 1914; Knutson, 1967). There is at least one case in which electrosleep was induced
where one electrode was placed on the forehead and the other on the subjects’ right palm
(Robinovitch, 1914). In 1966, the name changed to CET and shortly afterward a new dosage was
developed. Due to subject discomfort and the changing perception that penetration of current in
to the brain (including deep brain structures) did not require placement of electrodes directly on
top of the eyes (Brown, 1975; Richthofen and Mellor, 1979). Under this CET electrode montage,
the stimulation waveform was pulsed at 30-100 Hz, pulse width of 1-2 ms, at 0.1-0.5 mA
(Richthofen and Mellor, 1979). TCET was proposed as a new name for ES/CET but under this
new nomenclature the dose for TCET was unchanged in regards to electrode placement or
waveform (Brown, 1975).
A notable change in dosage occurred with the advent of NET and CES after 1970. In
NET and CES, the number of electrodes was reduced from 3 to 2 (Net Device Corp.; Kirsch,
2010; Liss Body Stimulator). The electrode placement for NET was in the subjects’ ears (NET
Device Corp. Information) - an approach later adopted by some CES devices with electrodes
clipped onto the ears (Kirsch, 2010). The waveform used in NET, and also in some later CES
devices, was 0.5–100 Hz stimulation at up to 600 µA over a period of 20 minutes (Kirsch, 2010;
NET Device Corp. Information). According to the manufacturer of the NET device model 804,
cartridges (Shown in Figure 2) were used to deliver specific dosages for different drug
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addictions. The other variant for CES devices uses 2 electrodes placed on top of the forehead.
The waveform for this variant of CES uses 15, 500 or 15000 Hz at 4 V with 50 ms pulses and
‘off’ periods of 16.7 ms (Datta et. al., 2013; Liss Body Stimulator Manual(M); Liss Body
Stimulator Manual(B)).

1.3.2 Electroanesthesia and derivative techniques
The dose for electroanesthesia evolved since the early 1900s. An early electrode
placement for EA/EN consists of 4 electrodes with either 2 electrodes applied to each temple or
to the bilateral frontal and occipital areas (Brown, 1975) however, there were other electrode
placement styles such as having the return electrodes placed on the subjects hand (Robinovitch,
1914). There are a wide range of frequencies and current intensities that were evaluated. As
noted, EA has been tested with pure DC requiring current approximately 40 mA to induce EA
(Brown, 1975; Robinovitch, 1914; Sances et. al., 1969). Under AC-only conditions, the
frequency ranged from 10–20 kHz with intensities approximately 10 mA (Geddes et. al., 1964);
higher current intensities were claimed to be needed with higher frequencies and currents of 500
mA and frequencies around 200 kHz have been used. When biased by DC, AC frequencies
typically remained in the same range with the AC component ranging from 2.5–5 mA with the
DC component also ranging from 2.5–5 mA (Brown, 1975). In some instances waveforms with a
high frequency of ‘ON’ periods were incorporated into TCES. TCES uses three electrodes rather
than the four in EA; the electrodes are positioned with a single electrode between the eyebrows
and two return electrodes on the retro-mastoid region (Brown, 1975; Limoge et. al., 1999). TCES
waveform consists of frequency trains. The high frequency portion of the train is ‘ON’ for 3-4
ms at 130-167 kHz and ‘OFF’ for 8ms periods. The low frequency portion (‘ON’/’OFF’) was
~77–100 Hz and the overall waveform uses 200-350 mA with 30-35 V (Limoge et. al., 1999).
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1.3.3 Transcranial Direct Current Stimulation / Transcranial Random Noise
Stimulation / Transcranial Alternating Current Stimulation
Developed over the last decade, Transcranial Direct Current Stimulation (tDCS),
Transcranial Random Noise Stimulation (tDCS), and Transcranial Alternating Current
Stimulation (tACS) are three different distinct forms of “contemporary” tES as far as waveform,
but all typically share the same approach in regards to electrode montage (number and shape). In
addition, though each applies a distinct waveform, in all cases the duration of stimulation is
typically 10-20 minutes with a peak current of a 1-2mA (Paulus, 2011). Conventionally, two
electrodes are used with one positioned “over” the target region and the other elsewhere on the
scalp (often the contra-lateral supraorbital region) or elsewhere on the body in at an extracephalic location (Paulus, 2010; Antal et. al., 2008; Zaehle et. al., 2010; DaSilva et. al., 2011).
Electrodes are typically saline soaked sponge material wrapped around a conductive rubber
electrode, though gel may also be used. In tDCS the (positive) anode and (negative) cathode are
distinguished for their actions on cortical excitability, and 1-2 mA is typically applied over 5-20
minutes (Paulus, 2010). For tACS, a single sinusoid at 10-40 Hz with a peak intensity of 0.4-1
mA has been tested (Antal et. al., 2008; Paulus, 2011; Zaehle et. al., 2010). The waveform
parameter for tRNS includes: “a frequency spectrum between 0.1 Hz and 640 Hz…[and]… a
normally distributed random level of current generated for every sample at a sampling rate of
1280 samples per second with no overall DC offset.” (Paulus, 2010; Chaiebet.al., 2009). One can
speculate if the increasingly complex waveforms used in CES approach noise-like action on the
brain.

1.3.4 “Transcranial Electrical Stimulation”
“TES” uses high-intensity pulses (150-1840 Volts, presumed to be voltage controlled)
lasting between 13-48 µsecs at an intermittent frequency of 1-3 seconds or much lower when
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used for monitoring purposes (Rossini et. al., 1985; Zentner et. al., 1989; Rothwell et. al., 1994;
Kalkman et. al., 1992). Typically stimulation is applied using a bifocal (and bipolar) montage,
but a “unifocal” montage has also been explored with an active electrode over the target a “ring”
of return electrodes, either as a single band or 12 separate electrodes, around the width of the
scalp (Rossini et. al., 1985; Rothwell et. al., 1994; Kalkman et. al., 1992).These techniques are
typically not with therapeutic intent, but rather to examine excitability for monitoring or
experimental purposes – though we are not aware of studies excluding any lasting effects.

1.3.5 Electroconvulsive Therapy
The waveforms for ECT are high-intensity, ~800 mA, with trains (AC or pulsed bursts)
lasting 1-6 seconds per cycle. The electrodes are placed either unilaterally or bilaterally on the
cranium and current intensity is typically increased by varying the number of pulses per train,
pulse duration, or intensity until a seizure is triggered (Gilula and Kirsch, 2005; Sackeim et. al.,
2000). Modern efforts to refine dose has focused on minimized memory loss for example
through focused stimulation, reviewed elsewhere (Spellman et. al., 2009; Datta et. al., 2008;
Rosa and Lisanby, 2012).

1.3.6 High Definition transcranial Direct Current Stimulation
HD-tDCS shares the same waveform with tDCS, 1-2 mA for 5-20 minutes, however the
large sponge electrodes used for tDCS (as for tACS/tRNS) are replaced with an array of smaller
electrodes. The electrode montage is then optimized for brain targeting for example the 4 x 1Ring montage uses a center electrode with determines the polarity of stimulation (anode or
cathode) and four return electrodes at ~4-7 cm radius. More broadly, High-Definition
Transcranial Electrical Stimulation (HD-tES) spans all efforts to focalize prior diffuse tES
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protocols by using arrays of HD electrodes to rationally guide current flow (Dmochowski et. al.,
2011).

Table 2: Different classes of tPCS are summarized including temporal waveform (function), the associated
magnitude spectrum (frequency content), and clinical references including dose using “CES”. The Fourier
series were generated using the same parameters for T, τ, and A across all classes and the same parameters
for h, D0, Ton, and Toff where applicable. Note n is a discrete function of 1/T (or T off in the case of Class III). In
Class III, the CES case would have D0 set to zero which would lower the peak at zero. In Class II, h r = (h+1)/h,
in Class III, Tr = Ton/Toff and in all classes, P = A(τ/T). The references indicated are:1Limoge, Robert, Stanley,
3
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tES technology across a century, presents a historical narrative with two overarching features: A)
Techniques incrementally evolved through five “streams” (Figure 1), and B) Individual
approaches fluctuate in popularity over time. Against this historical narrative of tES is the
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broader backdrop of medical research that, despite false starts and setbacks, did establish a swath
of drug and surgery based approaches as standards of neuropsychiatric care. The central question
thus appears: why given a century of research in tES does it remain marginalized compared to
other approaches to treat neuropsychiatric diseases and neurological disorders (Edelmuth et. al.,
2010)? More specifically, why did tES approaches continuously evolve during this period
without any given technique gaining traction and stability? Though historically pointed, this
question seems key in informing ongoing tES approaches and the ever-expanding array of
techniques and indications.
Historical tES publications, like all medical research, include an inherent positive bias,
and provide minimal clues as why a technique with presumably promising efficacy would be
abandoned (even by its existing users). But careful reading, including of conference notes,
indicates that concerns about side effects and complications seem to have motivated changes in
early tES approaches which generally employed relatively high currents (>10 mA). Parallel
pharmaceutical developments (e.g. antidepressants; Rosa and Lisanby, 2012) may have further
arrested tES development in regard to specific indications. But, these apparent setbacks in tES
are qualified by: 1) Increasing appreciation of the side-effects and limitations of drugs (Rush et.
al., 2006); 2) Recognition that therapeutic effects may require prolonged (repetitive) treatment
(early approach may have anticipated immediate effects), correct dosage, as well as proper
inclusion criteria (e.g. disease etiology); 3) Recognition that tES may be especially suited for
integration with cognitive or physical therapy for “functional targeting” (Cano et. al., 2013)
whereas much historical tES was applied in isolation (Rosa and Lisanby, 2012); 4) Enhancement
in anatomical targeting through computational model driven electrode montages including HighDefinition approaches where much historical tES used montages producing diffuse current flow,
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5) Lack of standardization (qualification, documentation, rational regulation) of tES approaches
(Edelmuth, et. al., 2010) since the precise dose of tES determines outcome; 6) Understanding the
success of any medical treatment is guided by not simply medical factors but also dissemination
and cost (and even societal stigma).
In the following six areas, ongoing (if early) successes with modern tES are emerging:
1) Cost/benefit: Modern tES treatment is researched as a “non-drug” alternative, in cases
with evaluation of efficacy against drugs (Brunoni et. al., 2013). As with many investigational
treatments, clinical trial inclusion in tES trials of individuals typically enroll patients who either
did not respond to drugs or could not tolerate the side effects – but the marketing of tES as a nondrug alternative specifically points to emerging concerns about drug medication (Jensen et. al.,
2013; Rosa and Lisanby, 2012). tES leaves no apparent “electrical residue” such that any
behavioral changes must result from lasting (therapeutic) changes in brain function, as opposed
to an apparent prolonged chemical presence with some drugs. In many indications the flat-line in
the percent of drug refractory patients (despite ever increasing number of marketed drugs), the
reliance on off-label drug prescriptions (where regulatory standards are ambiguous), increased
prescription drug abuse, and the need to curtail costs, all indirectly encourage new directions in
treatment. Thus patients, clinicians, and payers are anxious for new approaches, and few medical
techniques have favorable factors and momentum of tES.
2) Mechanism and biomarkers: Increased sophistication in (pre-clinical) biomarkers of
response (DosSantos et. al., 2012; Marshall et. al., 2011; Antal and Paulus, 2012; Zaehle et. al.,
2010; Schutter and Hortensius, 2011) with an associated emphasis on mechanism (Nitsche and
Paulus, 2011; Rahman et. al., 2013; Bikson et. al., 2004, Radman et. al., 2009; Spezia Adachi et.
al., 2012; Laste et. al., 2012; Marquez-Ruiz et. al., 2012), recognition of potential to titrate
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individual dose (Datta et. al., 2012), and increased duration of treatments- contemporary
approaches use more tolerated (<2 mA) approaches often applied over extended period of time
(e.g. weeks or months). Moreover, effects of tES were historically clinical, which have less
sensitivity than current measures such as transcranial magnetic stimulation (Cortes et. al., 2012)
– better biomarkers allow for direction of more subtle (pre-clinical) changes that can then inform
stimulation patterns / dose.
3) Integration with other therapies: Especially with contemporary tES approaches that
are well tolerated (including tDCS, tACS, and tRNS) it is convenient to combine stimulation
with various forms of directed physical and/or cognitive training. This form or training ranges
from motor physical therapy (including using robots; Edwards et. al., 2009; Nair et. al., 2011),
speech therapy (Torres et. al., 2013; Baker et. al., 2010), to training on higher cognitive functions
(Turkeltaub et. al., 2012). Thus in cases where physical or cognitive training has (moderate but
established) therapeutic benefit, tES is applied as an adjunct to “boost” the effects of therapy
(Martin et. al., 2013). In some cases the integration of low-intensity tES with training seems
obvious, as in conjunction with post-stroke rehabilitation, and in other cases creative, such as
pairing with visual illusions in neuropathic pain (Kumru et. al., 2013; D’Urso et. al., 2013) or
with behavioral therapy to target cognitive impairments associated with depression. Generally, it
remains to be investigated if tES is best applied before (e.g. priming), during, and/or after (e.g.
consolidation) of other therapies. The scientific rational includes reinforcement of electrical
stimulation effects with tES (Fritsch et. al., 2010; Bikson et. al., 2004). In addition, combining
other targeted therapies with tES allows for “functional targeting” where those processes (e.g.
synapses, networks) activated during tES are thus specifically modulated.
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Indeed, the effects of tES can be profoundly altered by brain state. The most obvious
example of this is if the subject observes, imagines, or performs voluntary movement, where the
evoked muscle response to brain stimulation (TES or TMS) is immediately stronger. However,
sustained tES with neuromodulatory intent has historically been delivered with the subject at
rest. Having the brain functionally engaged during or around the time of neuromodulatory tES
application has only recently been explored. The theoretical rationale for combining techniques
is unclear and may have started with tDCS and motor learning (Antal et. al., 2004). Since both
motor practice and tDCS could separately enhance voluntary performance (tDCS transiently) it
may have seemed logical that the combination could lead to a summed effect or enhancement.
Alternately, the tDCS may have been an appealing method to augment the physiological effects
of voluntary practice and learning, such as placing synapses in a more permissive state for
LTP/LTD induction, or facilitating consolidation that occurs in the post-practice period. Indeed
physiologic studies from around a decade ago, using non-invasive electric (tDCS) as well as
magnetic stimulation (TMS) show that there is a strong physiologic interaction of the static field
combined with TMS-synaptic activity (Lang et. al., 2004). The characteristics of the stimulation
(such as timing and dose) can change the observed excitability modulation - augment, reduce, or
even reverse the effect. Combining the NIBS with behavior should systematically test parameters
of stimulation and behavior, such that the combination is physiologically complementary
(Edwards et. al., 2009), and can lead to a desired functional outcome (Giacobbe et. al., 2013).
The relationship to brain excitability (MEP) and activity levels (EEG, fMRI, cMRI) have been
previously described, but remain incompletely understood, particularly in relation to function
and voluntary behaviour changes. Furthermore, change in behavior may not always be as
expected with tES neuromodulation when combined with behavourial/functional brain activity,
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and in some cases may lead to a transformation of the effect rather than simply a scaling
(Giacobbe et. al., 2013). The observed effects may critically depend on the time of assessment in
relation to the intervention (e.g. immediately post, next day etc).
And finally, the combined interventions in patients are likely to be influenced by diseasespecific pathophysiology, concurrent pharmacotherapy, altered biological response ceiling - that
can predispose for better or worse susceptibility of response, as well as the stimulation waveform
and montage. By testing the various combinations incrementally, it is likely that defined
interventions begin to show robust results across individuals and move therapies towards
optimum.
4) Targeting of brain regions: The relationship between tES dose (e.g. electrode
montage and waveform controlled by the operator) and underlying brain current flow is often not
trivial and computational “forward” models of tES are designed precisely to make this
connection – to predict which brain regions are stimulated for any given montage and so allow
rational selection of a preferred task-specific montage. Early models were generated analytically
(Rush and Driscoll, 1968) but advancement in numerical approaches (Wagner et. al., 2007),
leading to the introduction by our group of MRI-derived individual models with gyri-specific
resolution (Datta et. al., 2009) heralded a renaissance in the use and precision of these techniques
(Datta et. al., 2013; Bai et. al., 2013; Bikson et. al., 2012) and indeed the generation of new
montages such as the 4 x 1 High-Definition montage (Edwards et. al., 2013; Kuo et. al., 2012)
and automatic targeting (Dmochowski et. al., 2011). As noted above, the ability to titrate dose to
individuals (e.g. presence of stroke or TBI; Datta et. al., 2011; Datta et. al., 2010) or populations
(e.g. obese or children; Truong et. al., 2012) is supported by these same models. Combined with
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increased sophistication in “functional targeting”, better understanding of anatomical targeting
may fundamentally enhance tES efficacy and safety.
5) Qualification and Regulation: Changing tES dose is analogous to changing the
chemical composition of a drug (Peterchev, et. al., 2012), such that lack of control and
reproducibility will impair the constructive development of tES (Edelmuth et. al., 2010). With
the development of fully electronic controlled waveforms and current controlled stimulation,
inherent variability in device function was removed. But, especially in the CES stream of
development, with time there was an increased variety in devices and device settings. The turn of
the millennium marked a reversion to simplified and better-documented tES waveforms (e.g.
tDCS, tACS) and devices providing standardized waveforms (rather than a proprietary and
secretive blend), which provided a substrate for rational reproduction and testing by multiple
clinical teams.

We argue that the resurgence of research in precisely these contemporary

“simplified” approaches is directly related to the establishment and control of dose. Only by
reproducing tES dose, can mechanistic and clinical trials build incrementally and increase rigor.
Yet, in spite of this noted progress with contemporary approaches (or maybe because of the
resulting excitement / press), qualification and regulation remains a fundamental deficiency for
TES advancement in general.
There is wide dissatisfaction with the (lack) of regulation in modern tES. Even for those
who oppose any government restrictions, the lack of precise device qualifications (e.g. what is
tDCS) generates confusion and risk. FDA Quality Systems production standards and CE mark
provide one bar for rigor in hardware design but involve little medical science. The US FDA
regulation of tES is driven by commercial entities seeking marketing approval (i.e. only
company applications are considered) and so seems unlikely to provide general guidance on
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none-proprietary techniques like tDCS. The FDA further appears reluctant to either formally
approve or ban devices “cleared” (grand-fathered) over 30 years ago without compete medical
review. While at the same time the FDA clears more me-to (510k) products with a wide range of
dose parameters. General electrical safety standards from agencies such as IEC and UL are of
limited use as they provide limited and incomplete scientific/medical justification.
We propose the first and non-controversial hurdle is qualification, which requires precise
classification of TES by dose as well as inclusion criterion. This in turn allows correct
comparison across TES efforts and rational progress. The alternative is undocumented drift in
TES approaches and confusion about efficacy and safety. Indeed, this review is an attempt to
provide clarity on historical and contemporary methods, though we stop short of suggesting
specific testing methods for qualification. The anecdotal experience with microcurrent therapy
(discussed above) suggests lack of qualification, leading to confusion in clinic and market place,
can destroy and otherwise promising approach. We reiterate a basic principle often ignored:
devices producing different in any aspect of TES dose (waveform, electrode, duration….) are
distinct, just like drugs with different chemical composition are not the same.
6) Dose compliance monitoring: Leveraging rapid advances in electronics and
communication allowing development of devices that are simple to use, and provide more
consistent stimulation (including though targeting software; Dmochowski et. al., 2011) including
control of compliance by limiting and recording stimulation application timing and dose.
Historically, poor control and/or documentation of tES dose may have hampered identification of
real effects. Interestingly, despite available technological complexity (e.g. microcontroller driven
devices) the notable transition circa 2000 from increasingly complicated tES waveforms (e.g.
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proprietary commercial “blends”) to simpler waveforms (e.g. DC, one frequency sinusoidal AC)
may enhance reproducibility and rational progress.
With increasing medical and technological sophistication, and with recognition of these
six rules, we anticipate a much delayed “coming-of-age” for tES, leading to broad medical
adoption and acceptance over the next decade.
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2. A Finite Element Model View of Electrosleep
2.1 Introduction
Starting in the early 1900’s research on a form of stimulation called Electrosleep began
by Leduc and her group of researchers (Guleyupoglu et. al., 2013; Robinovitch, 1914).
Electrosleep’s original intention was to put the subject that was being stimulated to sleep. The
original montages that were used had the electrodes placed on the eyes with the rationale that
it was the best method by which to get current into the brain (Guleyupoglu et. al., 2013).The
method later changed to around the eyes as subjects complained about optic nerve irritation,
which could presumably be in regards to phosphenes appearing. This line of research continued
on for roughly 65 years until the first symposium for electrosleep and electroanesthesia where
the name changed to Cranial Electrostimulation Therapy (CET).
During these 65 years, many different electrode montages were tried and tested
however researchers always reported the same trend of stimulation leading to sleep. On top of
that, the electrode montages generally followed a pattern in placement where the electrodes
would be placed on opposite sides of the head. In the following models, the montages where
the active electrodes were on the forehead with varying returns on the mastoid were tested as
these are the closest to the original historic montage which consisted of the anodes being
placed on top of the eyes where some used a 2x2 configuration or a “hybrid,” a combination of
a sponge and High-Definition (HD) electrodes, 2x1 configuration.

2.2 Methods
Electrosleep models were generated to be solved using the Finite Element Method (FEM)
based on historic montages as well as a new montage. The montages were placed on the head
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using the International 10-10 system for electroencephalogram (EEG) electrode placement. In
each of these montages, there are two active electrodes on the front of the head and either one or
two return electrodes on the back of the head. The montages that were modelled were: Left eye
and right eye active sponges with left and right mastoid sponge returns; Over the left and right
eye active sponges with left and right mastoid sponge returns; AF3 and AF4 HD electrode active
with neck sponge pad return; and AF3 and AF4 HD electrode active with Iz sponge pad return.
All of the models used were derived from the same T1 magnetic resonance imaging (MRI) scan
that has a 1 mm3 spatial resolution. The MRI was taken of an adult healthy male. All models
were treated as volume conductors and they used the same method, except for electrode
placement, which can be separated into two different sections: model construction and solution.

2.2.1 Segmentation and Meshing
The masks that are used in the models were originally derived from a 1 mm3 resolution
MRI scan. The MRI scan was automatically segmented using a program call Statistical
Parametric Mapping (SPM8; Ashburner et. al., 2009). The automated segmentation separates the
MRI scan into six different tissues as follows: skin, bone, cerebral spinal fluid, air, gray matter,
and white matter (Figure 3). The automatic segmentation that was used was not ideal and further

Figure 3: Seven tissues (skin, fat, skull, cerebral spinal fluid (CSF), gray matter, white matter, and air) were
segmented using a combination of automated and manual techniques. Particular care was placed on
maintaining continuity of thin tissues such as bone and CSF, which were the most resistive and conductive
tissues respectively. Images are on the same scale.
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automated segmentation followed by manual segmentation was used to fill any holes left by the
previous software (Huang et. al., 2012). The manual segmentation also helped add in additional
detail

on

structures

like

the

cortical surface. Gaussian filters
were used to apply additional
smoothing for the surface of the
skin

mask.

The

workflow

preserves the resolution of the
anatomical 1 mm resolution data
(Bikson

and

Datta,

2012).

Additional masks were generated
using either manual segmentation
or using virtually created models
in Solidworks (DS SolidWorks,
MA)

that

were

placed

into

anatomically correct locations in
the MRI scan and consisted of:
Figure 4: 3D rendering of tissue segmentation based on a 1 mm
resolution MRI scan. (A) Transparent bone, CSF, white matter,
gray matter and opaque masks of the spinal cord, spinal nerves,
and intervertebral disks. (B) A zoomed in image of the spinal
segmentation including spinal cord, spinal nerves and
intervertebral disks. (C) Cranial nerves highlighted: Olfactory
Nerve (red), Optic Nerve (pink), and Vestibulocochlear Nerve
(blue). (D) Segmentation of the deep brain structures are shown.

Muscle, Optic Nerve,

Olfactory

Nerve, Vestibulocochlear Nerve,
Ligaments,

Intervertebral

Disc,

Spinal Cord, as well as all deep

brain structures (Figure 4). The manual segmentation, correction, filtering and the meshing that
was later performed was done using ScanIP+Fe (SIMPLEWARE LTD., UK).
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Before the segmentation model could be meshed, the electrodes, pads and electrogel had
to be modeled and imported into the segmentation model and then correctly positioned. Multiple
tools were used to accomplish this. A computer aided design (CAD) program known as
Solidworks (DS SolidWorks, MA) was used to create models of the electrodes and sponges that
were used. The models that were created were then exported as Standard Tessellation Language
(STL) files and then imported into ScanCAD (Simpleware LTD., UK) where the segmented
model was also loaded. The electrode, gel, and sponge models were then placed on the head and
then, using a built in function, converted into a mask.
There were four electrode configurations that were modeled:
(1) Sponge/HD electrode Hybrid: One electrode-sponge pad (5cm x 7cm) was placed
on the back of the neck (located centrally between the two mastoid regions) as the
cathode and two HD electrodes were placed on AF3 and AF4 as the anodes. The
sponges are typically soaked in saline and therefore given the conductance value of
saline whereas the gel was given its’ relative conductance and all electrodes were
given the conductance values that are highly conductive.
(2) Sponge/HD electrode Hybrid: One electrode-sponge pad (5cm x 7cm) was placed
on Iz as the cathode. Two anodal HD electrodes were placed on AF3 and AF4. The
sponges are typically soaked in saline and therefore given the conductance value of
saline and all HD electrode gels were given the conductance values of gel and HD
electrodes given the conductance values of an electrode.
(3) 12 mm Sponge, single return (2 x 2): Two cathodal 12 mm diameter sponges were
placed on behind the ears over the mastoid region. Two anodal 12 mm diameter
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sponges were placed on top of the eyes. The sponges are typically soaked in saline
and therefore given the conductance value of saline.
(4) HD electrode, double return (2 x 2): Two cathodal 12 mm diameter sponges were
placed on behind the ears over the mastoid region. Two anodal 12 mm diameter
sponges were placed above the eyes. The sponges are typically soaked in saline and
therefore given the conductance value of saline.
The linearity of our solution allows for the same solution to be applied to the opposite
polarity solution. The reason is that the “active” and “return” electrode selections are arbitrary in
that the directionality does not make a difference in regards to magnitudes (electric field and
current density magnitude). Also, due to the linearity, the solutions can be linearly scaled for any
DC current as well as any low frequency AC waveform that may be used.
When the segmented model was completed, with all of the masks properly segmented
and electrodes placed, the model was then meshed in ScanIP+Fe using an adaptive tetrahedral
meshing algorithm contained within the program. The final mesh that was produced contained
16.3 million elements and 22 million degrees of freedom for the Sponge/HD electrode hybrid
montages and 14.4 million elements and 19.6 million degrees of freedom for the pure small
sponge montages.

2.2.2 Finite Element Model
Once the segmentation models were meshed, they were then imported into a FE solver
known as COMSOL (COMSOL Multiphysics 4.3, COMSOL INC., MA). After the mesh was
imported into the solver, conductivities were assigned to each domain in the model (spine,
tissues, air, etc.). The electrical conductance’s (S/m) used were obtained from literature: Skin
(0.465), Skull (0.01), CSF (1.65), Gray matter (0.276), White matter (0.126), Air (1e-7),
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Electrode (5.8e7), Sponge (1.4), Gel (0.3), Muscle (0.16), Spinal Cord (0.171), Ligament
(0.251), Intervertebral Disk (0.161) (Wagner et. al., 2007; Parazzini et. al., 2014). The optic
nerve, olfactory nerve, pons, medulla oblongata, midbrain, fornix, corpus callosum, and
vestibulocochlear nerve were given white matter conductivities while the remaining structures
had gray matter conductivities assigned to them.
Surfaces that were exposed to air were designated as insulated bodies which includes any
point at which the model was truncated, namely at the base of the shoulders and chest. The only
areas that were not explicitly bounded as insulated were the surface of the electrodes. The
electrodes that were selected as anodes were designated to have an inward current of 0.5 A/m 2
each which gave a total of 1 A/m2 of inward current. For the cases in which a single return
sponge electrode was used, the sponge was delineated as a 0 V ground, which forces all 1 A/m 2
to the electrode. In cases where there were two return electrodes, one was selected to be the 0 V
ground while the other was assigned a -0.5 A/m2 inward current (or 0.5 A/m2 outward current).
All other boundaries in the model were delineated as continuous.
The models were solved to a relative tolerance of 1e-5 and after the solution was
completed, they were plotted in false color images of either electric field or current density as
noted in the figures. Since electric field is lower in deeper structures, current density was chosen
as the metric to display any stimulation that may occur.

2.3 Results
The segmentation generated a fairly typical looking skull, CSF, gray matter, white
matter, skin and fat for a healthy adult male (Figure 3). The added segmentation of deep brain
structures, cranial nerves, spinal cord, muscle, ligaments and intervertebral disks also were
typical (Figure 4).
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Electrodes placed on the eyes with the return on the mastoids generated the lowest
amount of cortical electric field as well as the lowest peak (Figure 5: A.1 – D.1). As the
electrodes were moved off the eyes, the area of the cortical surface in which there was an

Figure 5: Solution of the 4 montages that were tested in this investigation. The peak electric field is shown for
cortical surface and optic nerve and peak current density is shown for deep brain structures. The electric
field values are all scaled to a maximum of .375 V/m and current density values are scaled to a maximum of
0.075 A/m2. All values shown here are per mA of stimulation. Montages A, B, C, and D are as follows: Left
and Right Eye active, Left and Right Mastoid return; Over Left and Right Eye active, Left and Right
Mastoid return; AF3 and AF4 active, Neck return; AF3 and AF4 active, Iz return.
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electric field increased, however the peak electric only had a 0.1 V/m increase when it was
placed off of the eyes on either AF3/AF4 or directly above the eye (Figure 5: A.1, B.1, D.1). The
peak electric field went up another 0.1 V/m after the return electrode was moved down from
Iz, which is in line with the mastoid electrodes, to the neck (Figure 5: C.1). The area that the
electric field was present on the cortical surface also increases with the return electrode being
located lower on the head (Figure 5: C.1).
The deep brain structures also had a fairly noticeable difference when the historic
montages were compared against the new proposed montages. The peak current density was
the lowest with the electrodes placed on the eyes at 0.035 A/m 2 (Figure 5: A.2). The peak
increased by 0.01 A/m2 when the electrodes were moved off of the eyes and placed above
them (Figure 5: B.2). Although there was another 0.015 A/m2 increase with the electrodes
placed on AF3 and AF4, there was no difference between the return electrode being located on
either Iz or on the neck, at least in terms of peak current density (Figure 5: B-D.2). The return
electrode on the neck did however show an increase in overall current density on the brain
stem as well as deep brain structures when compared with the return on Iz (Figure 5: C.2, D.2).
There was also a large difference in the peak electric fields as well as electric field
distribution on the optic nerve. With the active electrodes placed on top of the eyes the peak
electric field that was predicted was 2.8 V/m (Figure 5: A.3). The value dropped by more than
half when the electrodes were placed above the eyes with the peak electric field at 1.2 V/m
(Figure 5: B.3). The distribution between B.3 and A.3 remained fairly similar however and most
of the electric field present on the part of the optic nerve prior to reaching the brain was >0.375
V/m. The electric field dropped again when the active electrodes were moved to AF3 and AF3
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and the cathode was on Iz from 1.2 V/m to 0.50 V/m (Figure 5: B.3, D.3). The electric field did
go up however when the cathode was moved to the neck from Iz with the peak at 0.65 V/m (a
0.15 V/m difference; Figure 5: C.3). The electric field distribution across the optic nerve had
higher peaks with a neck return however, was more spread out with an Iz return (Figure 5: C.3,
D.3). Overall, there was a large drop in electric field peaks between the historic and new
montages.

2.4 Discussion
The field of electrosleep began with a montage that consisted of placing electrodes on top
of the subjects’ eyes for the active and the return electrodes over the mastoids because it was
presumed that it was the best method by which to get electricity into the brain (Robinovitch,
1914; Brown, 1975). The electrodes were also moved off of the eyes to just above the eye for the
reason of optic nerve irritation. What is demonstrated by these models is that it is very possible
that there was an effect on the subjects’ eyes and optic nerve however, that placement on or just
around the eye is not the best method of stimulating the brain. The electric fields generated in the
brain with placement on AF3 and AF4 was anywhere between 50-100% higher than placement
on the eyes along with a close to 50% higher current density in the deep brain structures. The
reason for the drastic difference in these numbers could be related to the anatomy of the
surrounding area. The optic nerve, which would be the main conductor of the electric field after
the eyes, is mainly embedded in fat which is an insulating body. The significance of fat being
located there is that the current is trapped inside the higher conductance nerve until it touches
CSF. With the return electrodes being located on the very bottom portion of the brain, most of
the current will travel through the CSF straight to the return electrodes, as it is the path of least
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resistance. The higher the active electrodes are, in this case, the more electric field will be
generated on the cortical surface as well as in deep brain structures.
The difference between the electric field and current density distribution between the
return electrode on the neck and Iz are expected. Although the current density peak is the same
between the two, at 0.060 A/m2, the distribution will be different as with the lower electrode, the
path of the current will be different. The posterior portion of the brain with the electrode at Iz has
a greater amount of electric field since the electricity does not have to travel further down the
brain stem to reach the return electrode. However, some electric field is generated on the brain
stem regardless. In the case of the neck return, the electric field travels lower and thus, creates a
bigger distribution of current density across the brain stem.
The models demonstrate an interesting point in regards to the optic nerve, however. With
electric fields as high as 2.8 V/m it is not a surprise that phosphenes, or optic nerve irritation,
were being experienced by subjects who underwent historical electrosleep stimulation. The small
movement from on top of the eye to just above the eye reduces this electric field by half and is
reasonable as to why subjects found it to be more comfortable than before. The reason for the
distribution of electric field on the optic nerve is the same as for why such little electric field and
current density is produced on the deep structures of the brain as well as the cortical surface. The
optic nerve acts as a transmission line for the current and quickly changes direction towards the
return electrodes once the contact with CSF is made. As the goal is not to stimulate the eyes but
rather put a subject to sleep using stimulation, the newer montages aid with lowering the amount
of stimulation on the optic nerve while simultaneously increasing the stimulation in the brain
stem and the amygdala.
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2.5 Conclusion
Based on this modeling study, the newer montages that were investigated and compared
to the older montages have distinct advantages. Both montages have lower electric field
distribution

as

well

as

peaks

(from

2.8

V/m

and

1.2

V/m

to

0.65

V/m and 0.50 V/m; Figure 5: A-D.3) on the optic nerve. Both montages that were investigated
also have higher current density on the deep brain structures, which is almost double that of the
first montage used with the electrodes placed on top of the eyes (0.035 A/m2 to 0.060 A/m2;
Figure 5: A.3, C.3, D.3). The newer montages with the lower electric field on the optic nerve
would reduce the chance for phosphenes and increase the chances for an effect with higher
current density on deep brain structures. The electric field on the brain stem is also increased
which could also help increase the possible effect of sleep. However, this difference could be
smaller depending on where the researchers placed the electrodes as reporting on electrode
locations as well as waveform was unclear in the earlier studies (Guleyupoglu et. al., 2013).
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3. Electrosleep in Healthy Subjects
3.1 Background
Electrosleep has had a long history that has evolved into device companies and a field of
research today (Brown, 1975; Kirsch, 2010). The biggest question that remains is that if the early
researchers were actually able to put subjects to sleep, as it was claimed in many papers from
that time and was what coined the original term “electrosleep” (Robinovitch, 1914). From a
Finite Element Model (FEM) standpoint, we were able to discern that there is a possible effect
on sleep from the montages that were used back when electrosleep first started however, that
new montages explored by this same method may prove to be more efficacious in targeting
centers of the brain that may aid in sleep for the subject. One of the issues that the original
montage for electrosleep had was that it would cause optic nerve irritation (Brown, 1975). The
researchers who worked with electrosleep in the early 1900s did change their montages, however
the effect was further reduced in moving the electrodes to AF3 and AF4. The continuing research
also changed the stimulation parameters that were used. The original waveform of a monophasic
pulsed current at 100 Hz and 2 mA was changed to biphasic pulses as well as much different
types of pulses rather than the Class 1 pulses (Table 2).
An experiment to test the original, or as close to the original as possible due to changes in
how devices are made and better regulation of device output, can be done. The experiment would
be to investigate if there is an acute effect of electrosleep. The subject, when stimulated should
fall asleep and reawaken once stimulation is over if such an acute effect does exist. However, the
effects may also aid in falling asleep faster while the subject is undergoing transcranial Pulsed
Current stimulation (tPCS).
The tPCS experiment would be accomplished by using 100 Hz monophasic pulses to
stimulate a subject at different current levels, ranging from 0 mA to 2 mA. The montage that
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would be used is a “hybrid” 2 x 1 montage entailing HD electrodes placed on AF3 and AF4 and
a sponge electrode placed on Iz.

3.2 Methods
3.2.1 Electrical Device
The device that will be used will be a transcranial Pulsed Current Stimulator (tPCS) so
that pulsed currents may be applied to the brain. The device will be a current controlled device,
which in turn delivers variable voltage. The device shall output pulses at a 100 Hz frequency and
a 50% duty cycle which is determined by the following equation:
where

is the width of the pulsed and

is the frequency of the wave used in stimulation. The

device will be capable of delivering up to 2 mA peak of pulsed current to the subject, with the
average current being 1 mA. The electrodes used will be high definition electrodes as used in a
previous skin tolerability study (Minhas et. al., 2010). The device will also be modified so that it
will temporarily reduce the total amount of voltage used to pass the current to 30 V. This effect
will be achieved by having the device temporarily lower the current requirement until the skin
adapts and less voltage is needed to pass the desired current. Devices will also have a built in
“ramp” capability which enables the device to linearly increase to the desired current over a
period of 30 seconds.

3.2.2 Electrical Field Stimulation
Subjects will be stimulated once a week for 20 minutes, with one of the two stimulation
protocols from their group selected at random, for no more than 2 weeks. Subjects will be
required to have at least a one week wash out period prior to the next session of stimulation.
Stimulation will be administered at 2 mA, 1 mA, 0.5 mA and sham. Sham consists of a ramp up
and down at the start of stimulation with another ramp up and down at the end of stimulation.
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The area of stimulation will be checked daily before stimulation to ensure that no harm is being
done to the subject by stimulation with high definition electrodes. Electrodes will be placed on
AF3/AF4 anodes and Iz cathode.

3.2.3 In vivo experiments
Experiments will be conducted on healthy subjects. Subjects will be screened to check if
they have anxiety and to what degree their anxiety is currently at. Subjects will also be screened
for any skin conditions that they may have as they could be exacerbated by stimulation. The
scale that will be used during anxiety screening is the Hamilton Anxiety Rating scale (HAM-A;
Hamilton, 1959). Subjects will be excluded from the study if they score above 30 and any subject
that scores below this threshold will be included in the experiment. The reason for exclusion is to
ensure that subjects do have anxiety but that it is not too severe such that it may skew results as a
larger effect could possibly be seen from placebo on very anxious (>30 HAM-A score) subjects.
Subjects will be randomly placed into one of 4 different groups and will not know which
group that they have been placed into. The 4 groups, of 8 people each, will consist of 4 different
conditions and will be as follows:
1. 2 mA / Sham – Subjects will receive both sham and 2 mA tPCS 1 week apart
2. 1 mA / Sham – Subjects will receive sham and 1 mA tPCS 1 week apart
3. 0.5 mA / Sham – Subjects will receive sham and 0.5 mA tPCS 1 week apart
4. Sham / Sham – Subjects will receive 2 sessions of sham 1 week apart.
Subjects will be stimulated for 20 minutes in each session and the total session time
for each subject will be 40 minutes. The extension of the experiment beyond stimulation time is
to monitor for any post-stimulation effects as the effects may not onset in the short stimulation
time prior.
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Subjects will be administered a general quality of life questionnaire before and after each
day of stimulation. Along with these questionnaires, the subjects will repeat the HAM-A scale a
day after stimulation. Subjects will also have their eyes recorded during stimulation using an IRsensitive video camera as well as having a behavioral response being recorded from each subject
using an odd-tone response system. The subjects will hear low level tones and when a tone that is
different from the rest occurs, they will press a button to indicate that it occurred.

3.2.4 Calculations
As mentioned before, %duty cycle will be calculated with the following equation:

Where tp is the width of the pulse and f is the frequency of the wave used in stimulation. The
time averaged current will be calculated as a simple function of %duty cycle:

3.2.5 Analysis
Each group will have their HAM-A scores averaged for each session and the scores will
undergo an ANOVA to see if there are any significant differences in the scores from before they
started the first session. Scores will also be weighted for each session with the Visual Analog
Scale answers from the general well-being survey answers given by the subjects. These scores
will allow for subjective determinations of the subjects changes during stimulation and as a result
of stimulation.
The data collected by video will be analyzed for two things: iris occlusion and blink
speed. Taking the baseline wide open eye segment of the video, the rest of the video will be
compared against that to set a percentage of iris occlusion, or how much the eyelid has covered
the iris. For the measurement of blink speed, the video will be analyzed to see how long it takes

57
for blinks that the subject makes during the last 5 seconds of each minute. These two measures
will be used to analyze how sleepy a subject has become during the experiment. The more
occlusion of the iris there is, the sleepier the subject is and also is the case for blink speed, the
slower it is the closer a person is to falling asleep.
The final behavioral task of the odd-tone response will allow for reaction speed analysis.
The amount of time it takes will be analyzed for each (n>50) odd-tone response from the subject
to discern any changes in their ability to respond as the protocol goes on.

3.3 Expected Outcomes
2 mA / Sham tPCS: Subjects will fall asleep the fastest out of the real stimulation
protocols and the subject will also fall asleep quicker than sham stimulation. Subjects will have
decreased time to total iris occlusion as well as a decreased time to slower blink speeds. The
general health surveys will depict that subjects showed the greatest amount of relaxation during
stimulation than sham or other groups in their real stimulation protocol. The odd tone response
times will also be greater than the other real stimulation times. Subjects may also have a
reduction in anxiety as per the HAM-A results.
1 mA / Sham tPCS: Subjects will have a moderate effect in their outcome measures. The
time to sleep should be higher than the 0.5 mA condition however, lower than 2 mA stimulation.
The other times, including time to total iris occlusion and time to decreased blink speed, will also
have a difference from sham but not be as large as what should be seen in the 2 mA stimulation
condition. Subjects may also have a reduction in anxiety as per the HAM-A results.
0.5 mA / Sham tPCS: Subjects will have slight effects in their time to sleep as well as the
other measures such as time to total iris occlusion. The differences should not be as great due to
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the low amount of current and the lower amount of stimulation that reaches the areas of interest
in the brain. The resulting times and questionnaire answers may be discernable from sham.
Sham / Sham tPCS: Subjects may fall asleep during the experimental protocol due to
spending an extended period of time in a relaxing atmosphere however; the time to sleep will be
higher than the rest of the real portions of the experiment. The total iris occlusion times as well
as the time to decreased blink speed times will be greater than the other three groups during their
real portions. The sham portion for all experiments should be similar to both arms of this
experiment.

3.4 Discussion
Electrosleep started back in the early 1900s and even though it has had a large impact on
the field of modern neurostimulation in various ways, up to and including FDA approval, there
has been very little work done on verification on the purported claims of electrosleep. Given all
of the changes that have occurred over the years to the waveforms and montages of electrosleep,
it is understandable that the effects that have been achieved in the past may no longer be
achieved by what is currently used (Peterchev et. al., 2012). The purpose of this proposed
experiment is to verify if such an acute effect does exist with electrosleep.
The effects that have been claimed as a result of using electrosleep on subjects should
have an effect within the first session (Robinovitch, 1914). However, there are issues historically
in relation to the devices used that may preclude these effects to be replicated with such
intensity. The Leduc stimulator (Figure 2) used a mechanical interrupter where contact quality
between the wheel and probe could have caused issues in actual current delivered. The current
that was used could have also been variable as it is very possible that the devices used during the
early 1900s were voltage controlled rather than current controlled. The final issue is that Leduc's
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group reported time averaged current as their peak current rather than peak current where the
peak was 20 mA that was active 1/10th of the time, or a 10% duty cycle (Robinovitch, 1914).
Beyond the details found on this device, most other devices did not report on their waveforms
which could have also had similar details that can skew results.
The experiment proposed here may also have design factors that could preclude an effect
being found. The subject population, if the effect isn't as acute as claimed, could be too small to
discern any added effects in reducing time to falling asleep, increase in iris occlusion or other
measures by which the subjects response to the experiment, namely stimulation, is recorded. The
behavioral response from the odd-tone measure may also be unclear as the differences will be
small enough that large repetitions are required and there may not be enough during the period of
the experiment to achieve a significant result. Furthermore, having to respond to these odd-tones
may artificially increase the times that are required for falling asleep and the measures of
drowsiness.

3.5 Conclusion
While there are some limitations with this method of experimentation as explored in the
previous section, this method is a good start and something to expand on with more subjects and
possibly added outcomes measures. The overall effect may be discernable from a series of
experiments like the one proposed here.
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